CTAG1B
| Gene Description: |
cancer/testis antigen 1B |
| Synonyms: |
NY-ESO-1, LAGE-2, CTAG, CTAG1A, CTAG1, CTAG1B, ESO1, LAGE2B, CT6.1 |
| Orthologs: |
Human CTAG1B (protein-coding)
|
| |
|
Sources
Sources
|
Possible sources:
|
HomoloGene, MGD, RGD, Ensembl, Inparanoid, OrthoMCL, KEGG
|
|
|
|
Regions Overlapping this Feature:
Human: 1
Associated Regions: 1 Available
Regions were calculated based on variants available for a large study with a convincing p-value (P < 5 x 10-8) +/- 0.1cM, and then these regions were examined for genes based on the current set of T1DBase gene spans.
Gene Overview from Genome Browser
Top
Help
Cell Types Showing Expression: We do not have expression data for this gene.
Users should be aware that the scale represents a rank within an experiment rather than a normalized expression signal.
|
|
|
|
|
no data |
no data |
no data |
no data |
no data |
no data |
no data |
no data |
Expression Legend
The Beta Cell Gene Atlas is a collection of almost all available public microarray
data generated with pancreatic beta cells and related cell lines and types. The
expression data comes from 131 array analyses derived from 28 experiments
(open details in a new window).
The basal (untreated cell) expression signal intensity values in each array
were converted to ranks within the experiments; the highest value was used for
genes represented by more than one probe. The rank values of genes in a given cell
type were averaged with other calculated values from experiments performed with the
same cell type. The rank transformation of the expression values enable comparison
of gene expression across different organisms and tissues.
A red border around a cell indicates greater certainty in the data;
specifically, the gene has >0.95 probability of being expressed in the tissue.
Tissues Showing Expression: We do not have tissue expression data for this gene.
Interactions Table for CTAG1B:
The CTAG1B interactions are shown below. Each row lists the two interactors, the sources which document this as an interaction, a classification of the interaction as empirical or predicted, and Pubmed IDs (if any) for the interaction.
The table of interactions is downloadable as a text file. Please note that the text file will not include data from HPRD due to restrictions imposed by the HPRD funding sources.
Cross-Reference to Pathways and GO Terms
Top
Help
|
|
KEGG Network: None available
|
| |
|
|
|
|
Biocarta: None available
|
| |
|
|
|
|
Reactome: None available
|
| |
|
|
|
|
NCI-Nature Pathway Interaction Database: None available
|
| |
|
|
|
|
Gene Ontology: None available
|
| |
|
|
|
|
|
KEGG Network: None available
|
|
|
|
|
|
|
|
|
|
|
NCI-Nature Pathway Interaction Database: None available
|
|
|
|
|
Gene Ontology: None available
|
|
Publications: 65
-
Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo.
Liu Y, Tian X, Leitner WW, Aldridge ME, Zheng J, Yu Z, Restifo NP, Weiss R, Scheiblhofer S, Xie C, Sun R, Cheng G, Zeng G
J Biol Chem. 2011
PubMed ID: 21900253
-
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S
Proc Natl Acad Sci U S A. 2011
PubMed ID: 21933959
-
MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma.
Bujas T, Marusic Z, Peric Balja M, Mijic A, Kruslin B, Tomas D
Eur J Histochem. 2011
PubMed ID: 21556122
-
Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy.
de Carvalho F, Vettore AL, Inaoka RJ, Karia B, Andrade VC, Gnjatic S, Jungbluth AA, Colleoni GW
Cancer Immun. 2011
PubMed ID: 21247062
-
Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
Kudela P, Sun Z, Fourcade J, Janjic B, Kirkwood JM, Maillere B, Zarour HM
J Immunol. 2011
PubMed ID: 21131422
-
Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma.
Demirović A, Džombeta T, Tomas D, Spajić B, Pavić I, Hudolin T, Milošević M, Cupić H, Krušlin B
Pathol Res Pract. 2010
PubMed ID: 20591578
-
Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
Johannsen A, Genolet R, Legler DF, Luther SA, Luescher IF
J Immunol. 2010
PubMed ID: 20733200
-
Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.
Ayyoub M, Dojcinovic D, Pignon P, Raimbaud I, Schmidt J, Luescher I, Valmori D
Proc Natl Acad Sci U S A. 2010
PubMed ID: 20368442
-
Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor.
Chen JL, Morgan AJ, Stewart-Jones G, Shepherd D, Bossi G, Wooldridge L, Hutchinson SL, Sewell AK, Griffiths GM, van der Merwe PA, Jones EY, Galione A, Cerundolo V
J Immunol. 2010
PubMed ID: 20053942
-
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK, Jäger E
Int J Cancer. 2010
PubMed ID: 19728336
-
Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma.
Ries J, Mollaoglu N, Vairaktaris E, Neukam FW, Nkenke E
Anticancer Res. 2009
PubMed ID: 20044626
-
Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration.
Kim SH, Lee S, Lee CH, Lee MK, Kim YD, Shin DH, Choi KU, Kim JY, Park do Y, Sol MY
Lung. 2009
PubMed ID: 19795170
-
Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D
Clin Cancer Res. 2009
PubMed ID: 19531622
-
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM
J Immunol. 2009
PubMed ID: 19380770
-
Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.
Wang XY, Chen HS, Luo S, Zhang HH, Fei R, Cai J
Oncol Rep. 2009
PubMed ID: 19212631
-
Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
Oi S, Natsume A, Ito M, Kondo Y, Shimato S, Maeda Y, Saito K, Wakabayashi T
J Neurooncol. 2009
PubMed ID: 19030781
-
ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.
Schnurr M, Orban M, Robson NC, Shin A, Braley H, Airey D, Cebon J, Maraskovsky E, Endres S
J Immunol. 2009
PubMed ID: 19155470
-
Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
Grah J, Samija M, Juretić A, Sarcević B, Sobat H
Coll Antropol. 2008
PubMed ID: 18982744
-
Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Köbel M, Kalloger SE, Gilks CB, Watson PH, Nelson BH
PLoS ONE. 2008
PubMed ID: 18923710
-
Expression in childhood primary brain tumors of NY-ESO-1, a cancer/testis antigen: an immunohistochemical study.
Bodey B, Bodey V, Siegel SE
In Vivo. 2008
PubMed ID: 18396787
-
Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination.
Karbach J, Gnjatic S, Pauligk C, Bender A, Maeurer M, Schultze JL, Nadler K, Wahle C, Knuth A, Old LJ, Jäger E
Int J Cancer. 2007
PubMed ID: 17640060
-
Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population.
Ohkuri T, Sato M, Abe H, Tsuji K, Yamagishi Y, Ikeda H, Matsubara N, Kitamura H, Nishimura T
Cancer Sci. 2007
PubMed ID: 17488334
-
MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development.
Gjerstorff MF, Kock K, Nielsen O, Ditzel HJ
Hum Reprod. 2007
PubMed ID: 17208940
-
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, Ritter G, Eiermann T, Hossfeld DK, Zander AR, Jungbluth AA, Old LJ, Bokemeyer C, Kröger N
Blood. 2007
PubMed ID: 17023585
-
Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors.
Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, O'Neill D, Zavilevich K, Albukh T, Christos P, Mazumdar M, Pavlick A, Polsky D, Shapiro R, Berman R, Spira J, Busam K, Osman I, Bhardwaj N
Cancer Immun. 2007
PubMed ID: 17625806
-
Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system.
Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, Rao J, Li W, Chen D, Langford MP, Duggan C, Belldegrun AS, Dubinett SM
J Immunol. 2006
PubMed ID: 16951317
-
Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors.
Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME, Mahon TM, Karbach J, Jäger E, Cameron BJ, Lissin N, Vyas P, Chen JL, Cerundolo V, Jakobsen BK
J Immunol. 2006
PubMed ID: 16751374
-
Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H, Nishimura T
Int J Oncol. 2006
PubMed ID: 16596224
-
Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6).
Cho HJ, Caballero OL, Gnjatic S, Andrade VC, Colleoni GW, Vettore AL, Outtz HH, Fortunato S, Altorki N, Ferrera CA, Chua R, Jungbluth AA, Chen YT, Old LJ, Simpson AJ
Cancer Immun. 2006
PubMed ID: 17137291
-
Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue.
Hudolin T, Juretic A, Spagnoli GC, Pasini J, Bandic D, Heberer M, Kosicek M, Cacic M
Prostate. 2006
PubMed ID: 16114059
-
Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS
Cancer Res. 2005
PubMed ID: 16140944
-
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G
Blood. 2005
PubMed ID: 15671442
-
Structural and kinetic basis for heightened immunogenicity of T cell vaccines.
Chen JL, Stewart-Jones G, Bossi G, Lissin NM, Wooldridge L, Choi EM, Held G, Dunbar PR, Esnouf RM, Sami M, Boulter JM, Rizkallah P, Renner C, Sewell A, van der Merwe PA, Jakobsen BK, Griffiths G, Jones EY, Cerundolo V
J Exp Med. 2005
PubMed ID: 15837811
-
The DNA sequence of the human X chromosome.
Ross MT, Grafham DV, Coffey AJ, Scherer S, McLay K, Muzny D, Platzer M, Howell GR, Burrows C, Bird CP, Frankish A, Lovell FL, Howe KL, Ashurst JL, Fulton RS, Sudbrak R, Wen G, Jones MC, Hurles ME, Andrews TD, Scott CE, Searle S, Ramser J, Whittaker A, Deadman R, Carter NP, Hunt SE, Chen R, Cree A, Gunaratne P, Havlak P, Hodgson A, Metzker ML, Richards S, Scott G, Steffen D, Sodergren E, Wheeler DA, Worley KC, Ainscough R, Ambrose KD, Ansari-Lari MA, Aradhya S, Ashwell RI, Babbage AK, Bagguley CL, Ballabio A, Banerjee R, Barker GE, Barlow KF, Barrett IP, Bates KN, Beare DM, Beasley H, Beasley O, Beck A, Bethel G, Blechschmidt K, Brady N, Bray-Allen S, Bridgeman AM, Brown AJ, Brown MJ, Bonnin D, Bruford EA, Buhay C, Burch P, Burford D, Burgess J, Burrill W, Burton J, Bye JM, Carder C, Carrel L, Chako J, Chapman JC, Chavez D, Chen E, Chen G, Chen Y, Chen Z, Chinault C, Ciccodicola A, Clark SY, Clarke G, Clee CM, Clegg S, Clerc-Blankenburg K, Clifford K, Cobley V, Cole CG, Conquer JS, Corby N, Connor RE, David R, Davies J, Davis C, Davis J, Delgado O, Deshazo D, Dhami P, Ding Y, Dinh H, Dodsworth S, Draper H, Dugan-Rocha S, Dunham A, Dunn M, Durbin KJ, Dutta I, Eades T, Ellwood M, Emery-Cohen A, Errington H, Evans KL, Faulkner L, Francis F, Frankland J, Fraser AE, Galgoczy P, Gilbert J, Gill R, Glöckner G, Gregory SG, Gribble S, Griffiths C, Grocock R, Gu Y, Gwilliam R, Hamilton C, Hart EA, Hawes A, Heath PD, Heitmann K, Hennig S, Hernandez J, Hinzmann B, Ho S, Hoffs M, Howden PJ, Huckle EJ, Hume J, Hunt PJ, Hunt AR, Isherwood J, Jacob L, Johnson D, Jones S, de Jong PJ, Joseph SS, Keenan S, Kelly S, Kershaw JK, Khan Z, Kioschis P, Klages S, Knights AJ, Kosiura A, Kovar-Smith C, Laird GK, Langford C, Lawlor S, Leversha M, Lewis L, Liu W, Lloyd C, Lloyd DM, Loulseged H, Loveland JE, Lovell JD, Lozado R, Lu J, Lyne R, Ma J, Maheshwari M, Matthews LH, McDowall J, McLaren S, McMurray A, Meidl P, Meitinger T, Milne S, Miner G, Mistry SL, Morgan M, Morris S, Müller I, Mullikin JC, Nguyen N, Nordsiek G, Nyakatura G, O'Dell CN, Okwuonu G, Palmer S, Pandian R, Parker D, Parrish J, Pasternak S, Patel D, Pearce AV, Pearson DM, Pelan SE, Perez L, Porter KM, Ramsey Y, Reichwald K, Rhodes S, Ridler KA, Schlessinger D, Schueler MG, Sehra HK, Shaw-Smith C, Shen H, Sheridan EM, Shownkeen R, Skuce CD, Smith ML, Sotheran EC, Steingruber HE, Steward CA, Storey R, Swann RM, Swarbreck D, Tabor PE, Taudien S, Taylor T, Teague B, Thomas K, Thorpe A, Timms K, Tracey A, Trevanion S, Tromans AC, d'Urso M, Verduzco D, Villasana D, Waldron L, Wall M, Wang Q, Warren J, Warry GL, Wei X, West A, Whitehead SL, Whiteley MN, Wilkinson JE, Willey DL, Williams G, Williams L, Williamson A, Williamson H, Wilming L, Woodmansey RL, Wray PW, Yen J, Zhang J, Zhou J, Zoghbi H, Zorilla S, Buck D, Reinhardt R, Poustka A, Rosenthal A, Lehrach H, Meindl A, Minx PJ, Hillier LW, Willard HF, Wilson RK, Waterston RH, Rice CM, Vaudin M, Coulson A, Nelson DL, Weinstock G, Sulston JE, Durbin R, Hubbard T, Gibbs RA, Beck S, Rogers J, Bentley DR
Nature. 2005
PubMed ID: 15772651
-
Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
Qian F, Gnjatic S, Jäger E, Santiago D, Jungbluth A, Grande C, Schneider S, Keitz B, Driscoll D, Ritter G, Lele S, Sood A, Old LJ, Odunsi K
Cancer Immun. 2004
PubMed ID: 15521719
-
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Morrin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J, MGC Project Team
Genome Res. 2004
PubMed ID: 15489334
-
NY-ESO-1 expression and immunogenicity in esophageal cancer.
Fujita S, Wada H, Jungbluth AA, Sato S, Nakata T, Noguchi Y, Doki Y, Yasui M, Sugita Y, Yasuda T, Yano M, Ono T, Chen YT, Higashiyama M, Gnjatic S, Old LJ, Nakayama E, Monden M
Clin Cancer Res. 2004
PubMed ID: 15475443
-
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS
Proc Natl Acad Sci U S A. 2004
PubMed ID: 15252201
-
Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF
Clin Cancer Res. 2004
PubMed ID: 15240519
-
The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer.
Konishi J, Toyooka S, Aoe M, Omura Y, Washio K, Tsukuda K, Shimizu N
Oncol Rep. 2004
PubMed ID: 15069548
-
NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.
Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, Scanlan MJ, Ono T, Sakita I, Yasui M, Miyoshi Y, Tamaki Y, Matsuura N, Noguchi S, Old LJ, Nakayama E, Monden M
Cancer Res. 2004
PubMed ID: 15026363
-
Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C
Cancer Res. 2003
PubMed ID: 14583496
-
The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
Mandic M, Almunia C, Vicel S, Gillet D, Janjic B, Coval K, Maillere B, Kirkwood JM, Zarour HM
Cancer Res. 2003
PubMed ID: 14559844
-
High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector.
Batchu RB, Moreno AM, Szmania S, Gupta SK, Zhan F, Rosen N, Kozlowski M, Spencer T, Spagnoli GC, Shaughnessy J, Barlogie B, Tricot G, van Rhee F
Hum Gene Ther. 2003
PubMed ID: 14503968
-
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, Williamson B, Scanlan MJ, Ritter G, Chen YT, Driscoll D, Sood A, Lele S, Old LJ
Cancer Res. 2003
PubMed ID: 14522938
-
NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer.
Nakada T, Noguchi Y, Satoh S, Ono T, Saika T, Kurashige T, Gnjatic S, Ritter G, Chen YT, Stockert E, Nasu Y, Tsushima T, Kumon H, Old LJ, Nakayama E
Cancer Immun. 2003
PubMed ID: 12889868
-
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
Gnjatic S, Atanackovic D, Jäger E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ
Proc Natl Acad Sci U S A. 2003
PubMed ID: 12853579
-
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.
Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madan A, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ, Marra MA, Mammalian Gene Collection Program Team
Proc Natl Acad Sci U S A. 2002
PubMed ID: 12477932
-
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT
Immunol Rev. 2002
PubMed ID: 12445278
-
Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas.
Resnick MB, Sabo E, Kondratev S, Kerner H, Spagnoli GC, Yakirevich E
Int J Cancer. 2002
PubMed ID: 12209997
-
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.
Nagata Y, Ono S, Matsuo M, Gnjatic S, Valmori D, Ritter G, Garrett W, Old LJ, Mellman I
Proc Natl Acad Sci U S A. 2002
PubMed ID: 12138174
-
The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ.
Satie AP, Rajpert-De Meyts E, Spagnoli GC, Henno S, Olivo L, Jacobsen GK, Rioux-Leclercq N, Jégou B, Samson M
Lab Invest. 2002
PubMed ID: 12065688
-
[Expression of NY-ESO-1 gene in human esophageal carcinoma and its cloning]
Peng LP, Liu HY, Ran YL, Sun LX, Yu L, Yang ZH
Ai Zheng. 2002
PubMed ID: 12452034
-
NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM
Cancer Res. 2002
PubMed ID: 11782380
-
Multiple pathogenic and benign genomic rearrangements occur at a 35 kb duplication involving the NEMO and LAGE2 genes.
Aradhya S, Bardaro T, Galgóczy P, Yamagata T, Esposito T, Patlan H, Ciccodicola A, Munnich A, Kenwrick S, Platzer M, D'Urso M, Nelson DL
Hum Mol Genet. 2001
PubMed ID: 11709543
-
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma.
Goydos JS, Patel M, Shih W
J Surg Res. 2001
PubMed ID: 11397121
-
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues.
Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ
Int J Cancer. 2001
PubMed ID: 11351307
-
Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
Rimoldi D, Rubio-Godoy V, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis C, Cerottini JC, Lejeune F, Romero P, Valmori D
J Immunol. 2000
PubMed ID: 11120859
-
Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing.
Simpson JC, Wellenreuther R, Poustka A, Pepperkok R, Wiemann S
EMBO Rep. 2000
PubMed ID: 11256614
-
NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens.
Schultz-Thater E, Noppen C, Gudat F, Dürmüller U, Zajac P, Kocher T, Heberer M, Spagnoli GC
Br J Cancer. 2000
PubMed ID: 10901371
-
DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.
De Smet C, Lurquin C, Lethé B, Martelange V, Boon T
Mol Cell Biol. 1999
PubMed ID: 10523621
-
A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.
Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA
J Immunol. 1998
PubMed ID: 9759882
-
LAGE-1, a new gene with tumor specificity.
Lethé B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, De Plaen E, Boon T
Int J Cancer. 1998
PubMed ID: 9626360
-
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.
Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ
Proc Natl Acad Sci U S A. 1997
PubMed ID: 9050879
-
Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28.
Chen YT, Boyer AD, Viars CS, Tsang S, Old LJ, Arden KC
Cytogenet Cell Genet. 1997
PubMed ID: 9605863
Model Organism Phenotype Links from MGI
Top
Help
No mouse phenotype links available for this gene.
Relevant resources:
Home 
